Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients

Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission's (EC) approval of Praluent (alirocumab) for a new indication. The approval enables ... Read More